Barrow Hanley Mewhinney & Strauss LLC Grows Position in Sanofi (NASDAQ:SNY)

Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 113.8% in the 2nd quarter, Holdings Channel reports. The firm owned 5,943,547 shares of the company’s stock after acquiring an additional 3,164,092 shares during the period. Barrow Hanley Mewhinney & Strauss LLC’s holdings in Sanofi were worth $288,381,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Boston Partners grew its stake in shares of Sanofi by 0.3% during the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after buying an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp grew its position in Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after acquiring an additional 1,370,232 shares during the last quarter. Mondrian Investment Partners LTD increased its stake in Sanofi by 43.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the period. Envestnet Asset Management Inc. lifted its position in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the last quarter. Finally, Federated Hermes Inc. lifted its position in Sanofi by 26.5% in the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SNY shares. Argus raised their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a report on Friday. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Down 1.1 %

Sanofi stock opened at $57.63 on Friday. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The stock has a fifty day simple moving average of $54.34 and a two-hundred day simple moving average of $50.48. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market cap of $145.96 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 1.62 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.95 earnings per share. Equities analysts predict that Sanofi will post 4.25 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.